indol-3-yl piperidinomethyl ketone | 30256-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: indol-3-yl piperidinomethyl ketone
• 英文别名: 1-indol-3-yl-2-piperidin-1-yl-ethanone；1-(1H-indol-3-yl)-2-piperidin-1-yl-ethanone；Indolyl-(3)-piperidinomethyl-keton；3-Piperidinoacetyl-indol；Ketone, 3-indolyl piperidinomethyl；1-(1H-indol-3-yl)-2-piperidin-1-ylethanone
• CAS: 30256-73-6
• 化学式: C₁₅H₁₈N₂O
• mdl: MFCD00450894
• 分子量: 242.321
• InChiKey: CDRQAUBCVZVLOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  385.14°C (rough estimate)
• 密度：
  1.0388 (rough estimate)
• 溶解度：
  >36.3 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  36.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  indol-3-yl piperidinomethyl ketone 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 以99%的产率得到α-(piperidinomethyl)indole-3-methanol
  参考文献：
  名称：

  Fujii, Tozo; Ohba, Masashi; Sasaki, Noriko, Heterocycles, 1984, vol. 22, # 8, p. 1805 - 1810

  摘要：

  DOI：
• 作为产物：
  描述：

  吲哚 在 potassium carbonate 作用下， 以 乙醚 为溶剂， 反应 48.0h， 生成 indol-3-yl piperidinomethyl ketone
  参考文献：
  名称：

  杂环部分连接吲哚衍生物作为潜在抗菌剂的合成、表征和 ADME 预测研究

  摘要：

  背景：杂环化合物因其不同的药理特征而对研究至关重要。它们是当今市场上许多有效抗菌药物的关键结构成分，但仍面临微生物耐药性问题。吲哚及其衍生物具有镇痛、抗菌、抗抑郁、抗糖尿病、抗惊厥、抗蠕虫和抗炎等多种药理活性。通过 Schotten-Baumann 反应将咪唑、哌啶、哌嗪置于活性第 3 位，并进一步评估其对革兰氏阳性和革兰氏阴性菌的作用，以期开发出有效的抗菌剂。方法：在适当的条件下进行衍生物的合成，并通过 IR、NMR（1H 和 13C）和 CHN 元素分析对其进行表征。进一步的体外测定用于通过琼脂扩散和琼脂条痕稀释法对枯草芽孢杆菌 (ATCC 6633) 和大肠杆菌 (ATCC 25922) 的抗菌活性进行评估。还使用瑞士 ADME 在线程序计算了 ADME 特性。结果：化合物 4b、4f、4i、4k 在以抑制区 (17±0.5 mm-22±0.25 mm) 计算的两种体外测定中显示出最大效力和最小抑制浓度

  DOI：

  10.2174/1570180819666220404084045

文献信息

• [EN] CB1 MODULATOR COMPOUNDS<br/>[FR] COMPOSES MODULATEURS DE CB1
  申请人：LILLY CO ELI

  公开号：WO2005066126A1

  公开（公告）日：2005-07-21

  Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

  结构式（I）的新化合物已被披露。作为大麻素-1（CB1）受体的调节剂，这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面是有用的。因此，本发明的化合物在治疗、预防和抑制精神病、记忆缺陷、认知障碍、偏头痛、神经病、神经炎性疾病（例如多发性硬化症、吉兰-巴雷综合征和病毒性脑炎的炎症后遗症）、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面是有用的。这些化合物还可用于治疗物质滥用障碍，特别是对阿片类药物、酒精和尼古丁的治疗。这些化合物还可用于治疗与过度食物摄入及相关并发症相关的肥胖症或进食障碍。
• Cb1 antagonist compounds
  申请人：Allen Rebecca Jennifer

  公开号：US20070088018A1

  公开（公告）日：2007-04-19

  Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

  本发明揭示了化学结构式（I）的新型化合物。作为大麻素-1（CB1）受体的调节剂，这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面具有用途。因此，本发明的化合物在治疗、预防和抑制精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（例如多发性硬化症、吉兰-巴雷综合征和病毒性脑炎的炎症后遗症）、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面具有用途。这些化合物还可用于治疗物质滥用障碍，特别是阿片类药物、酒精和尼古丁。这些化合物还可用于治疗与过度食物摄入及其并发症相关的肥胖症或进食障碍。
• CB1 antagonist compounds
  申请人：Eli Lilly and Company

  公开号：US07276516B2

  公开（公告）日：2007-10-02

  Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith

  揭示了结构式(I)的新型化合物。作为Cannabinoid-1（CB1）受体的调节剂，这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面非常有用。因此，本发明的化合物在治疗、预防和抑制精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（例如多发性硬化症、格林-巴利综合征和病毒性脑炎的炎症后遗症）、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面非常有用。这些化合物也可用于治疗物质滥用障碍，特别是阿片类、酒精和尼古丁。这些化合物也可用于治疗与过度进食和相关并发症相关的肥胖或进食障碍。
• CB1 MODULATOR COMPOUNDS
  申请人：Allen Jennifer Rebecca

  公开号：US20080287504A1

  公开（公告）日：2008-11-20

  Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

  本发明揭示了化学式 (I) 的新型化合物。作为大麻素-1（CB1）受体的调节剂，这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面具有用途。因此，本发明的化合物在治疗、预防和抑制精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（例如多发性硬化症、格林-巴利综合症和病毒性脑炎的炎症后遗症）、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面具有用途。这些化合物还对治疗物质滥用障碍特别是对阿片类、酒精和尼古丁的治疗具有用途。这些化合物还对治疗与过度食物摄入和相关并发症有关的肥胖症或进食障碍具有用途。
• CB1 modulator compounds
  申请人：Eli Lilly and Company

  公开号：US07595339B2

  公开（公告）日：2009-09-29

  Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

  本发明揭示了结构式（I）的新化合物。作为Cannabinoid-1（CB1）受体的调节剂，这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面非常有用。因此，本发明的化合物在治疗、预防和抑制精神病、记忆障碍、认知障碍、偏头痛、神经病变、神经炎性疾病（例如多发性硬化症、格林-巴利综合征和病毒性脑炎的炎症后遗症）、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面非常有用。这些化合物还可用于治疗物质滥用障碍，特别是阿片类药物、酒精和尼古丁。这些化合物还可用于治疗与过度进食和相关并发症相关的肥胖症或进食障碍。